Werewolf Therapeutics, Inc. Common Stock
Here’s whether Werewolf Therapeutics, Inc. Common Stock (HOWL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.56% over 10 days); 3-month momentum positive (+96.9%); rising volume confirms the move (2.88x 30d avg). Concerns: RSI 94 — overbought, elevated pullback risk; weak 1-year return of -31.8%. Currently 63.3% off its 52-week high. Score: +4/7.
HOWL is in a confirmed uptrend, trading above both its 50-day ($0.39) and 200-day ($0.66) moving averages. With an RSI of 93.9, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -31.8% compares to +20.5% for SPY (trailed the market by 52.2%). The current 63.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.